Curaleaf Celebrates President Trump's Landmark Rescheduling of Cannabis Under Controlled Substances Act

Core Viewpoint - The Trump Administration's decision to reschedule cannabis as a Schedule III substance under the Controlled Substances Act is a significant federal reform that acknowledges the medicinal properties of cannabis and opens new opportunities for research, medical advancement, and investment [1][2]. Group 1: Impact of Rescheduling - Rescheduling cannabis to Schedule III will destigmatize the plant, allowing for federally funded clinical research, supporting veterans, and expanding patient access [2][3]. - The policy change eliminates onerous tax penalties and creates opportunities for increased investment in state programs, which can generate jobs and tax revenue for local communities [2][3]. Group 2: Public Support and Industry Commitment - The reclassification aligns with nearly 90% of U.S. adults who support legalization for medical or recreational use, reflecting widespread public support for cannabis reform [3]. - The company remains committed to the destigmatization and decriminalization of cannabis through community-based initiatives [3]. Group 3: Company Overview - Curaleaf Holdings, Inc. is a leading international provider of consumer cannabis products, known for quality and reliability, with a strong presence across the supply chain [4]. - The company operates under various brands, including Curaleaf, Select, and Grassroots, and is listed on the Toronto Stock Exchange and OTCQX market [4].